MYX mayne pharma group limited

Are we at the bottom, page-277

  1. 1,523 Posts.
    lightbulb Created with Sketch. 269
    No lifetime trend reversal here charts.
    No Shooting above 50c.
    This company due to several factors, primarily
    management is now extremely scrutinised.
    The August report for this current financial year
    will show considerable losses as we all know.
    We have also had large staff number increases
    to market E4. They indicated this would cost
    $10m for first 6 months. There may well be
    further writedowns although I doubt it.
    The bottom line Profit/ Loss statements are all
    that counts really. This is a business! Potential
    means Zippo. Tolsura is apparently an excellent
    product. They must increase sales. E4 is a contraceptive
    all said and done. I believe trying to change an individuals medication would not be easy. New patients ok but ones currently using extremely difficult. It will take
    time. This present management team are a pathetically
    slow moving mass of hopeless rabble stuck in a Timewarp of existence. They need Energy, Innovative
    Exciting Leadership. Across the Board. If it starts
    May the Top it can then radiate and flow throughout
    the company. This in turn becomes public Sales and productivity increase. New Products eventuate.
    Profits Happen, Share Price goes up.
    Theres no shooting stars out here Charts.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.08
Change
0.010(0.20%)
Mkt cap ! $412.7M
Open High Low Value Volume
$5.13 $5.15 $5.08 $445.2K 87.01K

Buyers (Bids)

No. Vol. Price($)
1 810 $5.08
 

Sellers (Offers)

Price($) Vol. No.
$5.15 2033 2
View Market Depth
Last trade - 16.10pm 27/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.